Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q1 2020 · 10-Q
Revenue$498.53M$498.53M+11.7% vs Q1 2019 Net Income$120.43M$120.43MN/M vs Q1 2019 EPS Diluted$0.78$0.78N/M vs Q1 2019 Gross Profit$183,499,000+120.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flow$49,026,000N/M Free Cash Flowderived$41,659,000N/M Margins · derivedGross margin36.8%+18.2 pt vs Q1 2019
Operating margin11.6%+32.7 pt vs Q1 2019
Net margin24.2%+34.9 pt vs Q1 2019
ended Mar 31, 2020 · filed May 11, 2020 · 41 d after period end